A new chemosensitivity assay for ascites tumor cells using a thermoreversible gelation polymer as a culture medium and the observed clinical responses

European Surgical Research

Volumn 39, Issue 1, 2007, Pages 41-50

  Isogai, Akiko ^a   Nagaya, Masaki ^a   Matsuoka, Hiromitu ^a   Watanabe, Taiji ^a   Tsukikawa, Satoshi ^a   Kubota, Sunao ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Ascites; Chemosensitivity test; Peritonitis carcinomatosa; Thermoreversible gelation polymer

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; POLYMER; UFT;

ADULT; AGED; ARTICLE; ASCITES; ASCITES FLUID; ASCITES TUMOR CELL; BONE MARROW SUPPRESSION; CANCER PATIENT; CARCINOMATOUS PERITONITIS; CHEMOSENSITIVITY; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; CULTURE MEDIUM; CYTODIAGNOSIS; DRUG BLOOD LEVEL; DRUG SENSITIVITY; FEMALE; GELATION; HUMAN; IC 50; LEUKOPENIA; MALE; PANCREAS CANCER; PRIORITY JOURNAL; RECTUM CANCER; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; STOMACH CANCER; SURVIVAL TIME; THREE DIMENSIONAL IMAGING; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; ASCITES; CELL CULTURE TECHNIQUES; CELL SURVIVAL; CISPLATIN; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; INJECTIONS, INTRAPERITONEAL; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PERITONITIS; RECTAL NEOPLASMS; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 33947236155     PISSN: 0014312X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000098439     Document Type: Article

References (30)

1. Yamaguchi T, Takahashi T, Sawai K, Hagiwara A, Taniguchi H, Yamagishi H: Treatment of postoperative recurrence of digestive cancers: peritonitis carcinomatosa (in Japanese). Nippon Geka Gakkai Zasshi 1999;100:211-215.
2. Yamada T, Ohira M, Hikishima H, Hashizume Y, Yamashita R, Iwa T: Intra-abdominal administration of CDDP in the management of carcinomatous peritonitis (in Japanese). Gan To Kagaku Ryoho 1986;13:1004-1009.
3. Yonemura Y: Effect of Chemotherapy on Carcinomatous Peritonitis in Peritoneal Dissemination (in Japanese). Tokyo, Health Syupan, 1996.
4. Heskins M, Guillet JE: Solution properties of poly (N- isopropylacrylamide). J Macromol Sci 1968;A2:1441-1445.
5. Yoshioka H, Mikami M, Mori Y, Kubota S: Preparation of poly (N-iso-propylacrylamide)-block-poly (ethyleneglycol) and calorimetric analysis of its aqueous solution. J Macromol Sci 1994;A31:109-112.
6. Yoshioka H, Mori Y, Tsukikawa S, Kubota S: Thermoreversible gelation on heating and on cooling of an aqueous gelatin-poly (N-iso-propylacrylamide) conjugate. Polym Adv Technol 1998;9:155-159.
7. Yamaue H, Tanimura H, Tsunoda T, Tani M, Iwahashi M, Noguchi K, Tamai M, Hotta T, Arai K: Chemosensitivity testing with highly purified fresh human tumour cells with the MTT colorimetric assay. Eur J Cancer 1991;27:1258-1263.
8. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
9. Carmichael J, DeGraff WG, Gazdar AF: Evaluation a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987;47:936-942.
10. Ishiyama M, Tominaga H, Shiga M, Sasamoto K, Ohkura Y, Ueno K: A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull 1996;19:1518-1520.
11. Takamatsu N: The new colorimetric assay (WST-1) for cellular growth with aging and Alzheimer's disease. Nippon Ronen Igakkai Zasshi 1998;35:535-542.
12. Wojtowicz J, Rzymshi K, Czarnecki R: A CT evaluation of the intra peritoneal fluid distribution. Rofo 1982;13:95-99.
13. Oken MM, Creech DC, Horto J, Davis TE, Carbon PP: Toxicity and response criteria of Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
14. Kondo T, Imamura T, Ichihashi H: In vitro test for sensitivity of tumor to carcinostatic agent. Gann 1996;57:113-121.
15. Idota C, Yamauchi M, Takagi H: SDI test using MTT for the evaluation of drug sensitivities of gastro intestinal cancer cells (in Japanese). Nippon Gan Chiryo Gakkai Shi 1990;28:85-93.
16. Saikawa Y, Kubota T, Furukawa T, Watanabe M, Kumai K, Ishibiki K, Kitajima M: Single-cell suspension assay with an MTT end point is useful for evaluating the optical adjuvant chemotherapy for gastric cancer. Jpn J Cancer Res 1994;85:762-765.
17. Graham CH, Kobayashi H, Stankiewics KS: Rapid acquision of multicellular drug resistance after a single exposure of mammary tumor cells to anticancer alkylating agents. J Natl Cancer Inst 1994;86:975-981.
18. Tanigawa N, Kitaoka A, Yamakawa M: Potential and limitation of scintillation assay (TIA) for clinical chemotherapy. Human Cell 1995;8:173-178.
19. Freeman AE, Hoffman RM: In vivo-like growth of human tumors in vitro. Proc Natl Acad Sci USA 1986;83:2694-2698.
20. Furukawa T, Kubota T, Watanabe M: High in vitro-in vivo correlation of drug response using spongegel-supported three-dimensional histoculture and MTT endpoint. Int J Cancer 1992;51:489-498.
21. Kubota T, Furukawa T, Kitajima M: High clinical predictability of histoculture drug response assay (HDRA) for drug-sensitivity of cancer of the digestive organs (in Japanese). Gan To Kagaku Ryoho 1993;20:461-466.
22. Furukawa T, Kubota T, Tanino H, Oura S, Yano T: Clinical application of histoculture drug response assay (HDDR) - distribution pattern of inhibition index and predictability of clinical chemotherapy effects (in Japanese). Gan To Kagaku Ryoho 1997;32:400-409.
23. Kubota T, Sasano N, Hoffman RM: Chemosensitivity test in evaluating adjuvant cancer chemotherapy of gastric cancer (in Japanese). Biotherapy 1996;10:847-853.
24. Samson DJ, Seidenfeld J, Ziegler K, Aronson N: Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 2004;22:3618-3630.
25. Hirabayashi K: Intraperitoneal chemotherapy (in Japanese). Gan To Kagaku Ryoho 1989;16:180-186.
26. Pretorius RG, Petrilli ES, Kean C, Ford LC, Hoeschele JD, Lagasse LD: Comparison of the i.v. and i.p. routes of administration of cisplatin in dogs. Cancer Treat Rep 1981;65:1055-1062.
27. Harada M: Pharmacokinetic and adverse-effect evaluations of total and unchanged cis-diamminedichloroplatinum (cisplatin, CDDP) after the intra-peritoneal administration in patients with carcinomatous peritonitis (in Japanese). Tokyo Jikeikai Med J 1998;113:147-155.
28. Namatame K, Kou Y, Nakayoshi A: The pharmacokinetics following intra-peritoneal infusion of cisplatinum with and without sodium thiosulfate rescue in the carcinomatous peritonitis in advanced gastric patients (in Japanese). Gan To Kagaku Ryoho 1991;18:1784-1790.
29. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rvoire M, Baulieux J, Fontaumard E, et al: Peritoneal carcinomatosis from non-gynecologic malignancies. Result of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88:358-363.
30. Takahashi T, Imai H, Ikawa A, Yasuda K, Kawai M, Yamamori T, Furuiti N, et al: Treatment of cancer ascites by combined intraperitoneal administration of low-dose CDDP and reinfusion of ultra-filtrated and concentrated ascitic fluid in patients (in Japanese). Jpn J Cancer Chemother 1999;26:1820-1824.